The European Commission has extended conditional marketing authorisation for Takeda’s Adcetris to include the treatment of CD30-positive cutaneous T-cell lymphoma (CTCL) following one prior systemic therapy.
Read More
Certain patients with Hodgkin’s Lymphoma living in England and Wales can now expect routine access to Takeda’s Adcetris on the NHS after NICE deemed the drug a cost-effective use of resources in some scenarios.
Read More
It is looking likely that patients with Hodgkin’s lymphoma will not be getting access to Takeda’s Adcetris on the National Health Service in England, after the drug was turned down again by cost regulators despite new data and a drop in price.
Read More
